Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 2 | 2 | — | — | — | 2 |
Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 1 | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 1 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 1 | — | — | — | 1 |
B-cell lymphoma | D016393 | — | — | 1 | 1 | — | — | — | 1 |
Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
Drug common name | BAZLITORAN |
INN | bazlitoran |
Description | Bazlitoran is an unknown pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Unknown |
Drug class | toll-like receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4297995 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 2U46M95B5M (ChemIDplus, GSRS) |